Back

Concluding question - ATTR-ACT Trial.

27 August 2018 (11:20 - 11:22)
Organised by:
Congress Presentation Part of: Hot Line Session 3 Neurologic Disorders and Heart Disease ESC Premium Access ESC Congress 2018

19 More presentations in this session

Presentation thumbnail
Opening question - ATTR-ACT Trial.
Slides Video
Presentation thumbnail
ATTR-ACT Trial - Efficacy and Safety of Tafamidis in Transthyretin Amyloid Cardiomyopathy
Professor C. Rapezzi (Ferrara, IT)
Slides Video
Presentation thumbnail
Discussant review - ATTR-ACT.
Professor J. George (Rehovot, IL)
Slides Video
Presentation thumbnail
Questions from the audience and discussion.
Presentation thumbnail
Opening question - COMMANDER HF.
Slides Video

Access the full session

Session thumbnail
Hot Line Session 3

The Event

Event poster

ESC Congress 2018

27 August 2018 11:20 CET
You may be interested in
thumbnail
Congress Presentation
ATTRibute-CM: ITT sensitivity analysis and sub-analysis comparing acoramidis and placebo in stage 4 CKD
11 May 2024
thumbnail
Congress Presentation
Prognosis changes in patients with transthyretin cardiac amyloidosis after attr-act study.
20 May 2023
thumbnail
Congress Presentation
Q&A
31 August 2025
thumbnail
Congress Presentation
Risks and benefits of antiplatelet therapy in patients with abdominal aortic aneurysm without symptomatic atherosclerotic disease: a nationwide cohort study
27 August 2023

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources